Joel Neutel
About
Joel Neutel is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery.
According to data from OpenAlex, Joel Neutel has authored 48 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Cardiology and Cardiovascular Medicine, 22 papers in Endocrinology, Diabetes and Metabolism and 16 papers in Surgery. Recurrent topics in Joel Neutel's work include Blood Pressure and Hypertension Studies (19 papers), Diabetes Treatment and Management (9 papers) and Hormonal Regulation and Hypertension (8 papers). Joel Neutel is often cited by papers focused on Blood Pressure and Hypertension Studies (19 papers), Diabetes Treatment and Management (9 papers) and Hormonal Regulation and Hypertension (8 papers). Joel Neutel collaborates with scholars based in United States, Israel and Canada. Joel Neutel's co-authors include Joseph L. Izzo, Gary F. Mitchell, Yves Lacourcière, Marc A. Pfeffer, Linda Kerwin, A. Jay Block, Thomas Marbury, Steven G. Chrysant, Nancy Buchanan and Victor F. Froelicher and has published in prestigious journals such as Circulation, Nature Medicine and SHILAP Revista de lepidopterología.
In The Last Decade
Joel Neutel
45 papers receiving 1.8k citations
Hit Papers
Peers
Joel Neutel
Emily K Marino United States
Harry Haber United States
Anastasios N. Lasaridis Greece
Graziana Lupattelli Italy
Masaru Hayashi Japan
Kohji Shirai Japan
Emmanuel Androulakis Greece
Nobutaka Hirai Japan
Yoh Miyashita Japan
Hiromichi Wakui Japan
Citations per year, relative to Joel Neutel Joel Neutel (= 1×)
peers
Emily K Marino
Countries citing papers authored by Joel Neutel
Since
Specialization
Citations
This map shows the geographic impact of Joel Neutel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Neutel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Neutel more than expected).
Fields of papers citing papers by Joel Neutel
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Joel Neutel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Neutel. The network helps show where Joel Neutel may publish in the future.
Co-authorship network of co-authors of Joel Neutel
This figure shows the co-authorship network connecting the top 25 collaborators of Joel Neutel. A scholar is included among the top collaborators of Joel Neutel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Neutel. Joel Neutel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Neeland, Ian J., Luiz Henrique de Gregório, Bo Åhrén, et al.. (2025). A Randomized, Placebo-Controlled, Single-Center, Crossover Study to Evaluate the Effects of Pre-Meal Whey Protein Microgel on Post-Prandial Glucometabolic and Amino Acid Response in People with Type 2 Diabetes and Overweight or Obesity. Metabolites. 15(1). 61–61.
2.
Johansen, Odd Erik, Joel Neutel, Sanjay Gupta, et al.. (2024). Oligomalt, a New Slowly Digestible Carbohydrate, Reduces Post-Prandial Glucose and Insulin Trajectories Compared to Maltodextrin across Different Population Characteristics: Double-Blind Randomized Controlled Trials in Healthy Individuals, People with Obesity, and People with Type 2 Diabetes. Metabolites. 14(8). 410–410.
3.
Véniant, Murielle M., Shu-Chen Lu, Larissa Atangan, et al.. (2024). A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nature Metabolism. 6(2). 290–303.
4.
Mohamed, Mafauzy, Kalpana Bhaskaran, Joel Neutel, et al.. (2023). A Randomized, Placebo-Controlled Crossover Study to Evaluate Postprandial Glucometabolic Effects of Mulberry Leaf Extract, Vitamin D, Chromium, and Fiber in People with Type 2 Diabetes. Diabetes Therapy. 14(4). 749–766.
5.
Neutel, Joel, Ram Gelman, Helena Katchman, et al.. (2023). Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial. SHILAP Revista de lepidopterología. 3(3). 417–425.
6.
Koren, Michael J., Patrick M. Moriarty, Joel Neutel, et al.. (2020). Abstract 13951: Safety, Tolerability and Efficacy of Single-dose Amg 890, a Novel Sirna Targeting Lp(a), in Healthy Subjects and Subjects With Elevated Lp(a). Circulation. 142(Suppl_3).
7.
Egan, Brent M., Henry Punzi, Sanjida Ali, et al.. (2018). CARDIOVASCULAR OUTCOMES WITH β-BLOCKER COMBINATION TREATMENT IN PATIENTS WITH HYPERTENSION: A LARGE, RETROSPECTIVE COHORT STUDY. Journal of the American College of Cardiology. 71(11). A1752–A1752.
8.
Eldor, Roy, et al.. (2018). Multiple Oral Insulin (ORMD-0801) Doses Elicit a Cumulative Effect on Glucose Control in T2DM Patients. Diabetes. 67(Supplement_1).
9.
Ballantyne, Christie M., Joel Neutel, William Duggan, et al.. (2014). =EFFICACY AND SAFETY OF BOCOCIZUMAB (RN316/PF-04950615), A MONOCLONAL ANTIBODY AGAINST PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IN STATIN-TREATED HYPERCHOLESTEROLEMIC SUBJECTS: RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY (NCT: 01592240). Journal of the American College of Cardiology. 63(12). A1374–A1374.
10.
Neutel, Joel, et al.. (2012). Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II Receptor Blocker Monotherapy. Advances in Therapy. 29(6). 508–523.
11.
Aranda, Juan, Garrie J. Haas, Joel Neutel, et al.. (2011). A PHASE I/IIA FIRST IN MAN SAFETY AND TOLERABILITY STUDY OF A NOVEL HNO DONOR, CXL-1020, IN PATIENTS WITH STABLE CONGESTIVE HEART FAILURE. Journal of the American College of Cardiology. 57(14). E299–E299.
12.
Neutel, Joel, et al.. (2011). Blood Pressure-Lowering Efficacy of an Olmesartan Medoxomil/Hydrochlorothiazide-Based Treatment Algorithm in Elderly Patients (Age ≥65 Years) Stratified by Age, Sex and Race. Drugs & Aging. 28(6). 477–490.
13.
Neutel, Joel, et al.. (2010). The Impact of Lactotripeptides on Blood Pressure Response in Stage 1 and Stage 2 Hypertensives. Journal of Clinical Hypertension. 12(3). 153–159.
14.
Kereiakes, Dean J. & Joel Neutel. (2010). Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring. Therapeutic Advances in Cardiovascular Disease. 4(5). 285–293.
15.
Kereiakes, Dean J., et al.. (2009). The Effects of an Olmesartan Medoxomil–Based Treatment Algorithm on 24‐Hour Blood Pressure Levels in Elderly Patients Aged 65 and Older. Journal of Clinical Hypertension. 11(8). 411–421.
16.
Saunders, Elijah, Greg Cable, & Joel Neutel. (2008). Predictors of Blood Pressure Response to Angiotensin Receptor Blocker/Diuretic Combination Therapy: A Secondary Analysis of the Irbesartan/Hydrochlorothiazide Blood Pressure Reductions in Diverse Patient Populations (INCLUSIVE) Study. Journal of Clinical Hypertension. 10(1). 27–33.
17.
Kaplan, Steven A. & Joel Neutel. (2006). Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. Urology. 67(2). 225–231.
18.
Julius, Stevo, Jay N. Cohn, Joel Neutel, et al.. (2004). Antihypertensive Utility of Perindopril in a Large, General Practice‐Based Clinical Trial. Journal of Clinical Hypertension. 6(1). 10–17.
19.
Chrysant, Steven G., et al.. (2001). Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension. Journal of Clinical Hypertension. 3(5). 283–318.
20.
Neutel, Joel, et al.. (1997). Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clinical Therapeutics. 19(3). 447–458.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Emily K Marino Breakdown of academic impact, for papers by Harry Haber Breakdown of academic impact, for papers by Anastasios N. Lasaridis Breakdown of academic impact, for papers by Graziana Lupattelli Breakdown of academic impact, for papers by Masaru Hayashi Breakdown of academic impact, for papers by Kohji Shirai Breakdown of academic impact, for papers by Emmanuel Androulakis Breakdown of academic impact, for papers by Nobutaka Hirai Breakdown of academic impact, for papers by Yoh Miyashita Breakdown of academic impact, for papers by Hiromichi Wakui